MyoKardia (MYOK) Insider Jake Bauer Sells 5,000 Shares

MyoKardia (NASDAQ:MYOK) insider Jake Bauer sold 5,000 shares of the firm’s stock in a transaction that occurred on Wednesday, April 11th. The shares were sold at an average price of $50.00, for a total transaction of $250,000.00. Following the sale, the insider now directly owns 66,777 shares of the company’s stock, valued at approximately $3,338,850. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Jake Bauer also recently made the following trade(s):

  • On Monday, March 26th, Jake Bauer sold 164 shares of MyoKardia stock. The shares were sold at an average price of $50.95, for a total transaction of $8,355.80.

NASDAQ:MYOK opened at $50.35 on Friday. MyoKardia has a 12 month low of $10.80 and a 12 month high of $62.83. The company has a market capitalization of $1,796.18, a price-to-earnings ratio of -35.89 and a beta of 3.64.



MyoKardia (NASDAQ:MYOK) last posted its earnings results on Thursday, March 8th. The biotechnology company reported ($0.21) EPS for the quarter, topping analysts’ consensus estimates of ($0.41) by $0.20. MyoKardia had a negative net margin of 204.48% and a negative return on equity of 24.58%. The business had revenue of $5.60 million during the quarter, compared to the consensus estimate of $5.63 million. equities analysts expect that MyoKardia will post -1.35 earnings per share for the current year.

Large investors have recently bought and sold shares of the business. SG Americas Securities LLC bought a new stake in MyoKardia in the 4th quarter worth approximately $185,000. Dimensional Fund Advisors LP bought a new stake in MyoKardia in the 3rd quarter worth approximately $212,000. Jane Street Group LLC bought a new stake in MyoKardia in the 4th quarter worth approximately $213,000. Paloma Partners Management Co bought a new stake in MyoKardia in the 4th quarter worth approximately $294,000. Finally, Teacher Retirement System of Texas bought a new stake in MyoKardia in the 4th quarter worth approximately $298,000. 83.49% of the stock is owned by institutional investors and hedge funds.

Several equities research analysts recently weighed in on MYOK shares. Cowen reissued a “buy” rating and set a $56.00 price target on shares of MyoKardia in a research report on Friday, March 9th. BidaskClub raised shares of MyoKardia from a “sell” rating to a “hold” rating in a research report on Monday, March 26th. Credit Suisse Group reissued an “outperform” rating and set a $60.00 price target on shares of MyoKardia in a research report on Thursday, January 18th. Wells Fargo reissued an “outperform” rating and set a $70.00 price target on shares of MyoKardia in a research report on Friday. Finally, Wedbush raised their price target on shares of MyoKardia from $51.00 to $69.00 and gave the company an “outperform” rating in a research report on Friday, March 9th. Three analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. MyoKardia has an average rating of “Buy” and an average price target of $65.57.

TRADEMARK VIOLATION NOTICE: This piece of content was published by Dakota Financial News and is owned by of Dakota Financial News. If you are reading this piece of content on another site, it was stolen and reposted in violation of U.S. & international trademark & copyright legislation. The legal version of this piece of content can be viewed at https://dakotafinancialnews.com/2018/04/13/myokardia-myok-insider-jake-bauer-sells-5000-shares.html.

About MyoKardia

MyoKardia, Inc is a clinical-stage biopharmaceutical company. The Company focuses on the treatment of heritable cardiomyopathies, a group of rare, genetically-driven forms of heart failure that result from biomechanical defects in cardiac muscle contraction. The Company is engaged in the business of developing and commercializing therapeutics.

Insider Buying and Selling by Quarter for MyoKardia (NASDAQ:MYOK)

Receive News & Ratings for MyoKardia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MyoKardia and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply